Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

LEGISLATIVE ALERT

On Monday, September 24, the Senate Health Committee will consider Senate Bill 977, which would establish  price controls for all drugs, biologics or healthcare technology that was developed partially or entirely through research and development supported directly or indirectly by Federal or State funds.

The biopharmaceutical industry is OPPOSED to this bill:

  • Subjecting medicines to price controls could lead to the stifling of innovation leading to less innovative treatments for patients and reducing R&D in New Jersey.
  • Price controls, whether applied to drugs or other goods, do not work and have unintended negative consequences.
  • The biopharmaceutical industry purchases more than $6 billion worth of goods and services from local New Jersey providers; represents nearly 20% of New Jersey’s GDP; and supports more than 10% of all the jobs in the state.
  • Spending on prescription drugs as a share of all health care spending in the US is the same as it was 60 years ago. Spending in the US on drugs accounts for about 10% of total health care spending. In fact, drugs account for a lower percentage of total health care spending in the US than in Europe, where drug price controls have been on the books for decades.
  • Biopharmaceutical research often includes research from public and private partnerships. About 73% of research dollars comes from the private sector in drug development, compared to 27% in public contributions.   However, it is the manufacturer that ultimately shepherds the medicine through the FDA process, including further R&D, testing, manufacturing and distribution.
  • R&D investment by America’s biopharmaceutical companies reached record levels in 2016: PhRMA member companies invested $65.5 billion in research and development (R&D) in 2016. PhRMA member R&D spending represents the vast majority of total biopharmaceutical industry R&D spending in the U.S., which the latest data from the National Science Foundation put at about $75 billion.  The U.S. pharmaceutical sector accounts for the single largest share of all U.S. business R&D, representing about 17% of all domestic R&D funded by U.S. businesses in 2014.
  • The average R&D cost required to bring a new FDA-approved medicine to patients is estimated to be $2.6 billion over the past decade (in 2013 dollars), including the cost of the many potential medicines that do not make it through the FDA approval. R&D costs increase because of increased clinical trial complexity, larger clinical trial size, greater focus on targeting chronic and degenerative diseases, and higher failure rates for drugs tested in earlier phase clinical studies.
  • While New Jersey remains the “Medicine Chest of the World,” the pharmaceutical industry is an evolving industry that faces formidable challenges. These include global economic pressures, regulatory demands and the impact of patent expirations on major products.

*************************************

We urge you to contact the members of the Senate Health Committee to register your opposition to this legislation.  Committee members are:

Thank you

How to Do Business with Pharma and Medical Technology Companies Annual Conference November 13

The HealthCare Institute of New Jersey (HINJ), Somerset County Business Partnership and Morris County Chamber of Commerce invite you to this special event, so you can learn how to do business with biopharmaceutical and medical technology companies and about the issues facing the life sciences industry, a pillar of New Jersey’s economy.

 

 

 

It will be held on Tuesday, November 13, from 8 a.m. to 12:30 p.m. at Porzio Life Sciences in Morristown.

Procurement executives from ELI LILLY, SANOFI and other life science companies will speak and answer your questions on how to become an industry vendor and will discuss trends in procurement and best practices.  Read more here.

Advance registration is required, which you can do online here or by calling 732-729-9622.

Seventh annual National Manufacturing Day event October 5 in Somerset

The seventh annual National Manufacturing Day event, sponsored by the New Jersey Manufacturing Extension Program Inc., will be held at The Marigold in Somerset on October 5  from 7:30 a.m. to 2:30 p.m. Read more and register here.

New Jersey’s Connected Economy: Measuring the Ripple Effect of Economic Policy

This in-depth new report from NJPRO, the New Jersey Policy Research Organization, is relevant to every industry in New Jersey, elected officials, and citizens.

The MedTech Conference, September 24-26 in Philadelphia

The MedTech Conference will be held in the Pennsylvania Convention Center.  Powered by AdvaMed, this annual event is expected to draw about 3,000 med tech business leaders and others.

Zwicker on biotech report: Public dollars, leveraged with private dollars, are key to innovation

Andrew Zwicker, who earned his Ph.D. in physics from Johns Hopkins and serves as the head of the Science Education Department of the Princeton Plasma Physics Laboratory, knows a little bit about funding. That is why the Democratic Assemblyman from the 16th District said he is optimistic about the direction the state is going. Zwicker served as vice chair of the state’s Biotechnology Task Force, which released a 44-page report June 13 on how to reinvigorate the state’s life science industry the right way.

Read more here.

The ‘State’ of New Jersey’s Innovative Industries

From New Jersey Business Magazine 

22 N.J. companies make 2018 Fortune 500 list

The annual Fortune 500 list of the nation’s biggest companies by revenue came out Monday, and 22 New Jersey companies made the cut — although only one placed in the Top 50.

That was New Brunswick-based Johnson & Johnson, which ranked 37th overall, with revenue of $76.45 billion. Newark-based Prudential Financial was the next-highest-ranked Garden State company, coming in at No. 52 with revenue of $59.69 billion.

Read more here.

With Taxpayers on the Brink, NJ Needs to Ease Off on Small Businesses

NJBIA President and CEO Michele Siekerka is urging policymakers to ease off on the litany of costly mandates and revenue raisers under consideration during this critical budget season.

In an op-ed in the Bergen Record, she observes  that Gov. Phil Murphy has proposed increasing taxes by $1.7 billion in the upcoming budget even as he prepares to sign legislation that will likely increase energy costs. This is on top of new laws ordering businesses to provide paid sick leave for all of their employees and increasing their liability in pay equity lawsuits.

Read more here.

Strong action is needed to preserve the competitiveness of America’s life-science industries

Washington D.C. – Living standards in the United States increasingly depend on the competitiveness of industries that compete internationally, particularly those that succeed by producing new innovations.

The life-science sector, which includes pharmaceuticals, biotechnology, and medical devices, is one of those industries. It is also an American success story: Our country captures more than 40 percent of the world’s major patents in both pharmaceuticals and medical devices. But as described in a new report written for the Information Technology and Innovation Foundation, the continued health of the U.S. life-sciences sector is at risk because a growing number of foreign competitors are making determined efforts to gain global market share, often using unfair tactics.

Read more here.